Methyldopate Hydrochloride, Methydopate Hydrochloride Injection

Type of Posting: Notice of Intent to Revise

Posting Date: 23-October-2020

Targeted Official Date: 01-August-2022, USP-NF 2022 Issue 2

Expert Committee: Small Molecules 2

In accordance with section 9.04(c) of the 2020–2025 Rules and Procedures of the Council of Experts, this is to provide notice that the Small Molecules 2 Expert Committee intends to omit the Methyldopate Hydrochloride and Methyldopate Hydrochloride Injection monographs.

USP may propose to omit a monograph from the USP–NF if the article is no longer marketed in the United States and where the monograph is not necessary to serve a public health need. Based on evaluation of the monographs, the Small Molecules 2 Expert Committee has determined that the Methyldopate Hydrochloride and Methyldopate Hydrochloride Injection monographs should be proposed for omission in the *Pharmacopeial Forum (PF)*.

USP Methyldopate Hydrochloride RS, associated with these monographs, is currently unavailable. USP does not intend to develop a replacement lot for USP Methyldopate Hydrochloride RS in anticipation of the omission of these monographs.

It is anticipated that the proposed revisions will be published in PF 47(2) [Mar.-Apr. 2021].

Should you have any questions, please contact Morgan Puderbaugh, Senior Scientific Liaison (301–816–8373 or mxp@usp.org).

CN-21-024-00

